MedikorPharma will distribute IsoRay’s products in Russian market, while Surgicorp in Peruvian market. Together with IsoRay’s other international distributors, MedikorPharma and Surgicorp are anticipated to support the company’s long term goals by obtaining increased recognition in the world marketplace for Cesium-131.

Utilizing of IsoRay’s Cesium-131 isotope, the company’s Cesium-131 products attack cancers in the prostate and other body sites, such as brain cancer, head and neck cancer, lung cancer and gynecological cancers.

IsoRay chairman and CEO Dwight Babcock said that all of the company’s products, except its just announced liquid Cesium-131 (Cesitrex) for use in its GliaSite radiation therapy system, currently carry the CE Mark, making them eligible to be sold in 31 European nations.

"Physicians and institutions throughout the US are continuing to report outstanding results in the use of our Cesium-131 seeds for brain cancer, head and neck cancer, prostate cancer, lung cancer and gynecological cancers," Babcock added.

Given this growing acceptance and interest, we remain committed to our strategic national and international marketing objectives and believe this will contribute to our long term success."